

Chikungunya (CHIKV) Infection Drug Development Pipeline Study, H2 2018

<https://marketpublishers.com/r/CB9A00E88DDEN.html>

Date: August 2018

Pages: 90

Price: US\$ 1,200.00 (Single User License)

ID: CB9A00E88DDEN

Abstracts

Chikungunya (CHIKV) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chikungunya (CHIKV) Infection pipeline products.

DISEASE OVERVIEW

Chikungunya fever is a viral fever, caused by Chikungunya virus (CHIKV), which belongs to the family *Togaviridae*. It is spread through *Aedes* species mosquito bites from infected person to healthy person.

Fever and joint pains are the primary symptoms while headache, muscle aches, swelling in joints and rashes are also found in patients infected with chikungunya fever.

Over the recent few years, mass outbreaks of the chikungunya infection are observed in Africa, Europe, Asia and Oceania. Currently, no treatment options or vaccines have been developed to treat/ prevent chikungunya virus infection.

To gain from the unmet demand for Chikungunya, 25+ companies are currently actively developing vaccines and treatment options. It is one of the most researched areas in infectious diseases with 25 therapeutic candidates in various stages of pre-clinical and clinical pipeline phases.

Companies participating in Chikungunya virus infection pipeline development include *Bharat Biotech International Ltd*, *Cilola*, *Ennaid Therapeutics LLC*, *Globavir Biosciences Inc*, *HSRx Group*, *Inovio Pharmaceuticals Inc*, *Integral Molecular Inc*, *Integrated BioTherapeutics Inc*, *Moderna Therapeutics Inc*, *Mymetics Corp*, *Najit*

Technologies, Paradigm Biopharmaceuticals Ltd, PaxVax Inc, Profectus BioSciences Inc, Riboscience LLC, Sementis Ltd, Singapore Immunology Network, Sun Pharmaceutical Industries, Takeda Pharmaceutical Co Ltd, Themis Bioscience GmbH, Valneva SE and Vaxart.

REPORT DESCRIPTION

The Chikungunya (CHIKV) Infection pipeline guide presents complete overview of drugs currently being developed for Chikungunya (CHIKV) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Chikungunya (CHIKV) Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Chikungunya (CHIKV) Infection pipeline candidates is included.

Major companies participating in therapeutic development of Chikungunya (CHIKV) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Chikungunya (CHIKV) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Chikungunya (CHIKV) Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Chikungunya (CHIKV) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF CHIKUNGUNYA (CHIKV) INFECTION PIPELINE REPORT INCLUDES

Panorama of Chikungunya (CHIKV) Infection pipeline markets including statistics on therapeutic drugs and companies involved

Chikungunya (CHIKV) Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Chikungunya (CHIKV) Infection pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Chikungunya (CHIKV) Infection pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Chikungunya (CHIKV) Infection pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire Chikungunya (CHIKV) Infection pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Chikungunya (CHIKV) Infection pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Chikungunya Infection Pipeline include-
Number of Companies with Chikungunya Infection projects in pre-clinical Development-
Number of Companies with Chikungunya Infection projects in Clinical Development-
Chikungunya Infection Pipeline Companies based in Americas
Chikungunya Infection Pipeline Companies based in Europe
Chikungunya Infection Pipeline Companies based in Asia Pacific
Chikungunya Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Chikungunya Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Chikungunya Infection Pipeline Agents in Clinical Development stage
Chikungunya Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Chikungunya Infection Pipeline agents

II. INSIGHTS INTO CHIKUNGUNYA INFECTION PIPELINE

1. Disease Overview
Introduction to Chikungunya Infection
Symptoms and Causes of Chikungunya Infection
Treatment or Prevention Options for Chikungunya Infection
Other Details
2. Phase wise Pipeline Compounds
Chikungunya Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Chikungunya Infection Pipeline- Phase 1 stage Drugs
Chikungunya Infection Pipeline- Phase 2 stage Drugs
Chikungunya Infection Pipeline- Phase 3 stage Drugs
Chikungunya Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Chikungunya Infection Pipeline Compounds
4. Chikungunya Infection Pipeline by Mechanism of Action

III. CHIKUNGUNYA INFECTION PIPELINE COMPOUND DETAILS

chikungunya virus vaccine
anti-viral peptide for Chikungunya

GBV006

HSRx

chikungunya vaccine

CHIKV-dmAb

IM-CKV063

neutralizing antibodies for Equine Encephalitis viruses and Chikungunya

mRNA-1388

mRNA-1944

CHIKV vaccine

Chikungunya virus vaccine(Najit/ABL)

Pentosan Polysulfate

Chikungunya VLP Vaccine

VesiculoVax-vectored vaccine

nucleoside analogs for the treatment of Dengue, Ebola, Chikungunya and Zika virus

dual acting vaccine(SCV1002)

SCV305

SIgN Human Monoclonal Antibody

antiviral therapeutics

TAK-507

Chikungunya virus vaccine(MV-CHIK)

VLA 1553

oral vaccine against Chikungunya Virus

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co-Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

IV. CHIKUNGUNYA INFECTION PIPELINE COMPANY BRIEFS

Bharat Biotech International Ltd

Cilola SAS

Ennaid Therapeutics LLC
Globavir Biosciences Inc
HSRx Group
Inovio Pharmaceuticals Inc
Integral Molecular Inc
Integrated BioTherapeutics Inc
Moderna Therapeutics Inc
Mymetics Corporation
Najit Technologies Inc
Paradigm Biopharmaceuticals Ltd
PaxVax Inc
Profectus BioSciences Inc
Riboscience LLC
Sementis Ltd
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Co Ltd
Themis Bioscience GmbH
Valneva SE
Vaxart Inc

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL CHIKUNGUNYA INFECTION PIPELINE MARKET

VI. APPENDIX

1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

I would like to order

Product name: Chikungunya (CHIKV) Infection Drug Development Pipeline Study, H2 2018

Product link: <https://marketpublishers.com/r/CB9A00E88DDEN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CB9A00E88DDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970